Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Primary APS
NCT05078710Phase 2Terminated
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2021
- Primary completion
- Jul 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of telitacicept in antiphospholipid syndrome (APS), sponsored by Peking Union Medical College Hospital. Started Jul 2021; status: terminated.
02
Drugs
telitacicept
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT05078710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05078710.